Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461626 | 0.84 | MEN1 (0.43) | — | |
| SCHEMBL293155 | 0.78 | TDP1 (0.72) | TDP1CYP11B1CYP11B2TNFPKM | |
| SCHEMBL293066 | 0.73 | TDP1 (0.70) | TDP1CYP11B1CYP11B2TNFLMNA | |
| SCHEMBL294217 | 0.72 | TDP1 (0.68) | TDP1CYP11B1CYP11B2TNFLMNA | |
| SCHEMBL511080 | 0.71 | TDP1 (0.78) | TDP1CYP11B1CYP11B2TNFPKM | |
| SCHEMBL462205 | 0.70 | GLS (0.48) | — | |
| SCHEMBL4313381 | 0.70 | CYP11B1 (0.62) | TDP1CYP11B1CYP11B2TNFPKM | |
| SCHEMBL30150452 | 0.70 | TDP1 (0.81) | TDP1CYP11B1CYP11B2TNFLMNA | |
| SCHEMBL12841561 | 0.69 | CYP11B1 (0.46) | TDP1CYP11B1CYP11B2TNFPKM | |
| SCHEMBL3161153 | 0.68 | TDP1 (0.84) | TDP1CYP11B1CYP11B2TNFLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815863-B2 | Hydrogen bond forming fluoro ketolides for treating diseases | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| EP-2613630-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Cempra Pharmaceuticals, Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2012034058-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Q6ZSR9, LSS, LCT | TDP1 3889/4885CYP11B1 1330/4885CYP11B2 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.